News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaBay Pharmaceuticals, Inc. Signs Option Agreement With Virbac Corporation (VBAC) Animal Health for Aganocide(R) Compounds



3/20/2012 9:49:22 AM

EMERYVILLE, Calif., March 20, 2012 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company today announced that it has entered into a feasibility and option agreement with Virbac Animal Health for the development and potential commercialization of Aganocides for a number of veterinary uses. NovaBay is developing its first-in-class, non-antibiotic, anti-infective Aganocide® compounds for the topical treatment and prevention of a wide variety of bacterial, viral and fungal infections.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES